Stay updated with breaking news from Foundation For Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Independent Director nominee expected to be elected at Annual Shareholders' Meeting in March 2024 CRANFORD, N.J., Jan. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. , a late-stage...
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") , a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced the nomination of seasoned pharmaceutical...
Aliso Viejo, CA (PRWEB) October 26, 2021 -- Aliso Viejo, CA —October 26, 2021 — RARE-X, a nonprofit organization dedicated to enabling patient communities to
Published: May 21, 2021 By Alex Keown Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers. AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she...
RARE-X Announces the Expansion of its Board of Directors to Support the Organization’s Growth and Launch Efforts Share Article New members will enhance RARE-X’s programs, pilots, and operational expansion with strategic expertise and leadership “The additions of Cynthia Grossman, PhD, Jason Colquitt, and Simon Frost to the board are very strategic. All bring a depth of knowledge in patient advocacy, health tech, scaling-up organizations, and operational excellence,” said Nicole Boice, RARE-X Co-Founder/Executive Director. ALISO VIEJO, Calif. (PRWEB) ...